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Abstract
Background: The utility of L-arginine and L-citrulline in treatment of arterial hypertension by
increasing vascular oxide nitric availability has been demonstrated. Photoplethysmography,
a simple and low-cost optical technique, makes it possible to assess vascular function and to
detect changes in blood flow, pulse and swelling of the microvascular tissular space. The aim of
the study was to evaluate the effect of L-citrulline supplementation on functional class, ejection
fraction and peripheral blood flow in patients with systolic heart failure.
Methods: Thirty-five stable outpatients attending the Heart Failure Clinic at the INCMNSZ
underwent clinical evaluation, radioisotopic ventriculography and photoplethysmography before and
at the end of 4 months. They were randomized into two groups: experimental group, with oral
L-citrulline supplementation (3 g/day, n = 20) and control group, without supplementation (n = 15).
Results: In the experimental group the left ventricular ejection fraction (LVEF) increased
20.3% at rest and 12.7% with stress, as well as the right ventricular ejection fraction at rest of
15.10% and 14.88% with stress. In addition, functional class improved in 35%, and the
maximum amplitude time/total time (MAT/TT) index decreased 23.1%. These changes were
statistically significant compared with the control group.
Conclusions: Citrulline supplementation significantly improved the LVEF, the endothelial
function (MAT/TT index) and functional class. Citrulline can be an important co-adjuvant in
the treatment of stable and stable systolic heart failure patients. (Cardiol J 2012; 19, 6: 612–617)
Key words: citrulline, systolic heart failure, endothelial function
Introduction
Heart failure (HF) is a clinical syndrome result-
ing from damage to myocardial fibers. The main
causes are acute or chronic ischemia, hypertension
and arrhythmias [1]. There are several molecular
mechanisms involved, including apoptosis, oxida-
tive stress, inflammation, endothelial dysfunction
and cardiac remodeling [2, 3]. HF is associated with
increased activity of angiotensin-converting en-
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zyme (ACE) and diminished peripheral blood flow,
both of which diminish synthesis of nitric oxide
(NO) and increase endothelin-1 [2, 3].
NO is responsible for maintaining regulated
vasodilatation [4]. NO originates with amino acids
from the diet (glutamine and glutamate) that,
through several reactions in the intestine, are trans-
formed into citrulline. After its absorption, it arrives
at the kidney, where the enzymes arginossuccinate
synthase and lyase transform it into arginine, which
is converted into NO plus citrulline. The citrulline
can be transformed in arginine again, providing
a recycling axis [4–9] it has been hypothesized that
because of the efficiency of the recycling systems
the amount of NO produced exceeds the quantity
of citrulline formed at a rate of 8:1 [8].
Arginine is the supplement more frequently
used, but the drawback is that its hepatic metabo-
lism consumes a great part of it [4]. Glutamine sup-
plements have been studied, but only 27% is con-
verted into citrulline [10]. Van de Poll et al. [5] de-
monstrated that the generation of citrulline through
glutamine represented only 13% of the intestinal
metabolism [5–9]. The characteristic of citrulline is
that it is absorbed completely without any hepatic
consumption [10], suggesting that it could be a bet-
ter supplementation choice [6, 10].
Rougé and des Robert [9] administrated oral
citrulline in a dose of 0.18 g/kg/day and observed
that neither urinary arginine, plasmatic urea nor ex-
cretion of nitrates were altered, suggesting that this
supplementation was associated with an increased
nitrogen balance, and an anabolic effect. In this
study plasmatic citrulline increased 5 times (490%)
with oral supplementation while less than 1% of the
citrulline was excreted in the urine, implying that
the oral route has good absorption [11, 12].
A comparison of arginine and citrulline supple-
mentation in patients with diastolic HF patients and
pulmonary hypertension from our clinic showed that
after 8 weeks of treatment systolic pulmonary pres-
sure diminished, and right ventricular ejection frac-
tion (RVEF) rose. Better results were obtained with
citrulline [13].
Rector et al. [14] demonstrated that patients
with HF and left ventricular ejection fraction
(LVEF) of 18 ± 5% who received oral L-arginine
(5.6–12.6 g/day) for 6 weeks achieved a significant
improvement in blood flow in one extremity and
lower production of endothelin-1. Likewise, when
Böger and Bode-Böger [15] administered 8 g/day
of L-arginine for 4 weeks to patients with HF and
LVEF of 19 ± 9%, they found an 8.8% improvement
in vasodilatation in the radial artery.
The objective of the present study is to evalu-
ate the effect of L-citrulline supplementation on
functional class, ejection fraction and peripheral
blood flow in patients with systolic HF. This will
complement our previous work on the effect of NO
precursors on diastolic HF and pulmonary hyper-
tension.
Hypothesis
In systolic HF patients oral L-citrulline supple-




From February to July of 2011 outpatients re-
ceiving treatment in the Heart Failure Clinic at the
Instituto Nacional de Ciencias Médicas y Nutrición
“Salvador Zubirán” were recruited. Subjects included
men and non-pregnant women more than 18 years
of age with a confirmed diagnosis of systolic HF in
NYHA functional classes I and II. Systolic HF was
defined as signs and symptoms of HF and LVEF of
£ 35% measured by echocardiogram and/or radio-
isotopic ventriculography. Patients were excluded
if they had myocardial ischemia susceptible to re-
vascularization, recent myocardial infarction, unsta-
ble angina or a myocardial revascularization proce-
dure, including percutaneous transluminal coronary
angioplasty and aorto-coronary by-pass grafting,
a cerebrovascular event within the last 3 months,
dysfunctional prosthetic valve, obstructive or non-
obstructive hypertrophic cardiomyopathy, uncor-
rected congenital heart disease, active myocarditis,
a history of resuscitation after sudden death, or
severe arrhythmias.
All patients received standard HF therapy (diu-
retics, ACE inhibitors, angiotensin II antagonists,
aldosterone receptor blockers, digitalis and beta-
-adrenoreceptor blockers), according their maximum
doses tolerated.
After baseline measurements, patients were
randomly assigned to one of the following groups:
1) control group, without supplementation and op-
timal pharmacological treatment (n = 15) or 2) ex-
perimental group (n = 20) who received 3 g/day of
L-citrulline malate powder in two doses of 1.5 g in
addition to conventional therapy considering the
dose suggested in the literature [9, 11–13]. Inves-
tigators and study personnel with any participation
on the study were blinded to the characteristics,
evaluation of patient and treatment group allocation.
Supplements were provided as weighed daily
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amounts to be taken as a drink mixed with juice or
water throughout the day, during the 4-month treat-
ment period. Compliance was evaluated using the
supplement consumption records kept daily by pa-
tients, and by collecting the empty containers.
The study was approved by the Institutional
Ethics Committee of biomedical Research in Hu-
mans of the INCMNSZ, and all patients signed in-
formed consent forms.
Radio-isotopic ventriculography technique
Left and right ventricular functions at rest and
in exercise were evaluated by radio-isotopic ven-
triculography, which is one of the simplest tech-
niques to provide an initial functional evaluation
among HF patients [16–18].
The procedure was performed at rest in the
supine position using in vivo red blood cell labeling
with technetium-99m by standard methods [19].
The patients were required to fast for 4 h prior
to the study and refrain from caffeine for 24 h. They
were injected with 40 mg of stannous pyrophos-
phate in 1.5 mL saline. Ten minutes later, the pa-
tients were positioned on the bed of the camera with
the detector in the right anterior oblique (RAO)
position. A rapid bolus of 20 mCi technetium-99m
pertechnetate was given intravenously, together
with the start of a list mode acquisition. Following
the first pass study and after time for equilibration
in the blood volume, a standard gated cardiac blood
pool study was acquired in the left anterior oblique
(LAO) and left lateral projections. The R to R in-
terval was divided into 16 frames, not greater than
0.04 s in length. Multigated acquisition was record-
ed for 900 s in a 64 × 64 matrix. Quantization was
performed on the LAO view. Processing and mea-
surements were made according to the American
Society of Nuclear Cardiology Society guidelines.
Also, all participants were studied with a mul-
tistage exercise treadmill test according to the
Bruce modified protocol. Systolic and diastolic blood
pressures were recorded by cuff when the subject
was standing immediately before testing and dur-
ing the last minute of the last exercise stage. Sub-
jects exercised until reaching and age-specific tar-
get heart rate or the development of symptoms
necessitating termination of the test.
Photoplethysmography
A baseline digital photoplethysmographic wave
was recorded for 30 s. The forearm was then com-
pressed with a sphygmomanometer cuff for 5 min
using a pressure of 30 mm Hg above the systolic
arterial pressure recorded (ischemic phase). The
compression was then released and the digital pho-
toplethysmographic wave was recorded for 120 s.
The wave was analyzed at 30 s intervals for com-
parison with the baseline values. The most repre-
sentative waves were selected from the recording
of each interval, and the maximum amplitude time
(MAT) and total time (TT) were measured in or-
der to calculate the MAT/TT index. A MAT/TT in-
dex of less than 30 was considered normal, as pro-
posed in other studies [20, 21].
All evaluations were performed at the begin-
ning and 4 months after initiating supplementation
by a cardiologist who was blinded to the patient’s
study group.
Statistical analysis
Continuous variables were expressed as mean ±
± standard deviation (SD), and categorical variables
as absolute and relative frequency. For comparisons
between the 2 groups at baseline c2 or Fisher’s
exact test for categorical and the Mann-Whitney U test
for continuous variables were used. To compare the
changes from baseline to 4 months between the
groups, percentage of change between the initial
and final measurements was calculated and Mann-
-Whitney U test was used. A p value of < 0.05 was
considered statistically significant. All analyses were
performed using a commercially available package
(SPSS for Windows, version 17.0 SPSS Inc.).
Results
Three of the 38 patients recruited were elimina-
ted, one from the citrulline group because of gastrointes-
tinal intolerance, and two from the control group be-
cause they left the study. Thus, 20 patients consti-
tuted the citrulline group and 15 the control group.
Table 1 shows the baseline clinical character-
istics of both groups. The main co-morbidities were
hypertension, diabetes mellitus, and ischemic heart
disease. The hemodynamic baseline characteristics
appear in Table 2.
The comparisons between the results obtained
after the intervention in each group are presented
in Table 3. In the group receiving L-citrulline in-
creases in the LVEF at rest of 20.3% and 12.7% with
effort, as well as the RVEF at rest of 15.10% and
14.88% with effort are evident. These phenomena
were not observed in the control group, in which
LVEF decreased 6.47% at rest and 12.6% with ef-
fort, and RVEF decreased 10.7%.
An improvement in functional class occurred
in 35% of the patients in the experimental group
(p = 0.016). Patients reported less dyspnea, while
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Table 1. Clinical baseline characteristics of study groups.
Variable L-citrulline group (n = 20) Control group (n = 15) P
Age (years) 68.2 ± 9.3 65.8 ± 9.5 0.36
Gender (women/men) 4/16 7/8
New York Heart Association I 10 (50%) 11 (73.3%) 0.16
New York Heart Association II 10 (50%)  4 (26.7%)
Co-morbidities:
Systemic hypertension 14 (70%) 13 (86.7%) 0.42
Ischemic heart disease 17 (85%) 10 (66.7%) 0.25
Diabetes mellitus 10 (50%) 8 (53.3%) 0.85
Dyslipidemia 11 (55%) 1 (6.7%) 0.03
Atrial fibrillation 4 (20%) 3 (20%) 1.00
Hypothyroidism 3 (15%) 3 (20%) 1.00
Treatment:
Angiotensin converting enzyme inhibitor 8 (40%) 4 (26.7%) 0.41
Angiotensin receptor antagonist 11 (55%) 7 (46.7%) 0.63
Beta-blocker 18 (90%) 11 (73.3%) 0.37
Aspirin 12 (60%) 10 (66.7%) 0.69
Loop diuretic 6 (30%) 7 (46.7%) 0.31
Statins 9 (45%) 5 (33.3%) 0.49
Digitalis 15 (75%) 8 (53.3%) 0.18
Amiodarone 2 (10%) 2 (13.3%) 1.00
Nitrates 6 (30%) 6 (40%) 0.54
Table 3. Comparison of changes in blood pressure, cardiac and endothelial function between study
groups.
Percentage of change L-citrulline group Control group P (% change)
Systolic blood pressure [%] –2.02 ± 9.36 7.08 ± 17.08 0.15
Diastolic blood pressure [%] –3.22 ± 14.01 –1.42 ± 14.12 0.99
Rest left ventricular ejection fraction [%] +20.30 ± 40.32 –6.47 ± 18.08 0.03
Rest right ventricular ejection fraction [%] +15.10 ± 41.80 –10.72 ± 42.2 0.09
Stress left ventricular ejection fraction [%] +12.71 ± 32.6 –12.6 ± 19.8 0.04
Stress right ventricular ejection fraction [%] +14.88 ± 33.7 1.80 ± 45.62 0.22
Maximum amplitude time/total time index [%] –23.13 ± 21.07 15.99 ± 25.4 < 0.001
Table 2. Hemodynamic baseline characteristics of study groups.
Variable L-citrulline group (n = 20) Control group (n = 15) P
Systolic pressure [mm Hg] 113 ± 17.2 118 ± 15.8 0.46
Diastolic pressure [mm Hg] 70.3 ± 11.5 76.7 ± 11.0 0.93
Rest left ventricular ejection fraction [%] 22.11 ± 6.7 29.53 ± 9.2 0.02
Rest right ventricular ejection fraction [%] 32.0 ± 14.4 29.0 ± 11.2 0.76
Stress left ventricular ejection fraction [%] 24.4 ± 8.6 34.0 ± 9.1 0.005
Stress right ventricular ejection fraction [%] 32.9 ± 11.7 27.4 ± 13.9 0.17
Maximum amplitude time/total time index [%] 28.2 ± 9.1 29.07 ± 7.11 0.43
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in the control group there was no change, except
for 2 patients who went from NYHA II to III, with-
out statistical significance.
The MAT/TT index decreased 23.3% in experi-
mental group compared to the control group.
Discussion
L-arginine is a precursor of citrulline that at
concentrations of 0.5–1 mmol/L acts as a scaven-
ger of reactive oxygen species and reduces lipid
peroxidation and O2 release from endothelial cells
[22]. At high concentrations it regulates the bind-
ing of macromolecules to red blood cells, decreas-
ing blood viscosity [23].
Several NO-independent actions of L-arginine
have been described: regulation of pH (intracellu-
lar and intravascular); contribution to the depolar-
ization of endothelial cell membranes; antioxidant
properties; decrease of blood viscosity; precursor
for the synthesis of proteins, urea, polyamines and
other amino acids; stimulation of the release of hor-
mones such as insulin, glucagon, prolactin and
growth hormone; stimulation of fibrinolysis; de-
creased formation of thromboxane B2; inhibition of
the platelet-fibrin complex; enhanced plasmin gen-
eration and enhanced fibrin degradation [24, 25]. It
is an ACE inhibitor that contributes to the regula-
tion of blood pressure [26].
The search for new alternatives to improve cli-
nical condition in patients with HF and optimize phar-
macological treatment opens lines of investigation
that attempt to delay ventricular deterioration over
time. In this study we found significant changes in
functional class and LVEF after citrulline supplemen-
tation compared to the control group.
A prior study from our clinic [13] also found
a MAT/TT index reduction that could be interpreted
as improved distribution of peripheral blood flow.
This could be attributed to a constant supply of the
NO precursor, which probably maintained vasodi-
latation independent of endothelial synthesis, re-
ducing friction stress. Since we observed changes
in both pre-ischemic and post-ischemic periods
during the test, it could indicate improved vascular
reactivity, as Rector et al. [14] and Böger and Bode-
-Böger [15] postulated when they measured blood
flow in extremities, and reduced resistance affect-
ing left ventricular ejection effort.
Our findings let us suppose there is better pe-
ripheral tissue perfusion, particularly of muscle
mass, resulting in a better functional class. While
this study cannot determine the exact mechanism
of citrulline, it certainly demonstrates a positive
effect on endothelial function. This peripheral va-
sodilatation probably reduces the difficulty to ven-
tricular ejection allowing them to be more efficient.
Perivascular delivery of L-arginine reduced
vascular remodeling and neointimal thickening af-
ter balloon dilatation of rabbit coronary artery [27].
In addition, intravenous infusion of L-arginine en-
hanced cardiac performance in patients with severe
congestive HF, mainly by affecting systemic vas-
cular resistance [28] increasing maximum vasodi-
latation during reactive hyperemia and reducing
peripheral resistance in patients with HF [29, 30].
Although there were differences between the
groups on some hemodynamic baseline characte-
ristics, the improvement on patients’ percentage of
change after citrulline supplementation in contrast
with those on control group, especially in stress
LVEF in a short period, could be explained with an
improvement in stress RVEF, increasing with this
the left ventricle filling volume, but with worse
peripheral vasodilatation (increase in MAT/TT in-
dex and systolic blood pressure) and hence decreas-
ing the ejection fraction on stress.
Supplementation based on citrulline seems to
be the optimal choice, since as Van de Poll et al. [5]
and Rougé et al. [9] described; the lack of hepatic
metabolism does not limit the dose and could rep-
resent an advantage. Citrulline can be an important
adjuvant in the treatment of patients with compen-
sated systolic HF. Future investigations are re-
quired to increase follow-up and the number of sub-
jects to evaluate the long term effects.
Limitations of the study
This study is limited both non-placebo-controlled
open label design, and by the small sample size
Conclusions
The supplementation of citrulline during
4 months in patients with systolic HF improved
functional class, LVEF at rest and effort, and vasodi-
latation independent of endothelial function. So cit-
rulline can be an important co-adjuvant in the treat-
ment of patients with systolic HF.
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